Now there are two: Modern’s mRNA COVID-19 vaccine 94.5% successful, joins Pfizer-BioNTech collaboration in targeting pandemic

screen shot at am
Credit: Photo Illustration by Rafael Henrique/SOPA Images/LightRocket via Getty Images

The Moderna vaccine reduced the risk of Covid-19 infection by 94.5%. There were 95 cases of infection among patients who received placebo in the company’s 30,000-patient study. There were only five infections in patients who developed Covid-19 after receiving Moderna’s vaccine, mRNA-1273.

Moderna also released data about the number of patients who had severe Covid-19. There were 11 cases of severe disease, all of them in the placebo group — … [a] point of encouragement for [Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases].

“There was always the concern … since the primary endpoint [of the trial] is just clinically apparent disease, how do we know it’s going to have an impact on severe disease? And the results with severe disease were striking — 11 to zero is very impressive,” he said. At the time of their data release, Pfizer and BioNTech had no severe cases in their study.

Related article:  Gates Foundation awards $12 million to teams hunting for universal flu vaccine

Further, Fauci said the Moderna vaccine appears to have been protective in important subsets of participants — the elderly and people from racial and ethnic minority groups, the latter of which make up 37% of the Moderna trial population.

The Moderna vaccine is given in two doses, 28 days apart.

Read the original post

Outbreak
Outbreak Daily Digest
Biotech Facts & Fallacies
Genetics Unzipped
Infographic: How dangerous COVID mutant strains develop

Infographic: How dangerous COVID mutant strains develop

Sometime in 2019, probably in China, SARS CoV-2 figured out a way to interact with a specific "spike" on the ...
Untitled

Philip Njemanze: Leading African anti-GMO activist claims Gates Foundation destroying Nigeria

Nigerian anti-GMO activist, physician, and inventor pushes anti-gay and anti-GMO ...
News on human & agricultural genetics and biotechnology delivered to your inbox.
glp menu logo outlined

Newsletter Subscription

Optional. Mail on special occasions.
Send this to a friend